Eylea Biosimilar Launch Comes Earlier Than Expected, Putting Regeneron Under Pressure
Amgen will launch a biosimilar version of Regeneron’s top-selling drug Eylea “at risk” following a US Court of Appeals decision denying an injunction.
Amgen will launch a biosimilar version of Regeneron’s top-selling drug Eylea “at risk” following a US Court of Appeals decision denying an injunction.